- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Pharmakonzern Stada: Nachträglich mehr Geld für Aktionäre | Hartnäckigkeit kann sich für Anleger auszahlen. Zur Höhe der gezahlten Abfindung beim Stada-Squeeze-Out sind immer noch Klagen ehemaliger Aktionäre anhängig. So ist der aktuelle Stand. Der Hintergrund:... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 65,36 | +0,68 % | Ionis Pharmaceuticals skizziert Strategie für 2026: TRYNGOLZA-Expansion und wichtige Studiendaten im Fokus | ||
| CSPC PHARMA | 1,034 | +0,98 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE ... | ||
| SELLAS LIFE SCIENCES | 4,990 | -4,22 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,275 | +3,32 % | Acadia Pharmaceuticals beruft Jonathan M. Poole in den Verwaltungsrat | ||
| CATALYST PHARMACEUTICALS | 21,290 | -0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 374,90 | +0,40 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ENZON PHARMACEUTICALS | 0,033 | +6.400 % | Enzon Pharmaceuticals, Inc: Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock | ||
| OPUS GENETICS | 4,500 | +9,36 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,700 | +0,43 % | Savara receives FDA day 74 letter for autoimmune PAP drug | ||
| GALECTIN THERAPEUTICS | 2,900 | +3,57 % | Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March ... | NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,906 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients | ||
| NOVABAY PHARMACEUTICALS | 1,270 | +8,55 % | XFRA B9P1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNOVABAY PHARMACEUTICALS... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,041 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Preclinical Data in Huntington's Disease Presented at ASENT |
LOTUS PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.